Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20512108 | 0.84 | CA12 (0.42) | ALDH1A1TSHRMEN1KMT2ATP53 | |
| SCHEMBL17797782 | 0.82 | TSHR (0.66) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL2655059 | 0.80 | ALDH1A1 (0.56) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL20512015 | 0.80 | L3MBTL1 (0.43) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL1164342 | 0.80 | LMNA (0.59) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL14984028 | 0.79 | TSHR (0.68) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL29860709 | 0.79 | TSHR (0.65) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| Alcohol SCHEMBL27463083 | 0.78 | ALDH1A1 (0.73) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL28237720 | 0.78 | TSHR (0.59) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL6909225 | 0.78 | ALDH1A1 (0.62) | ALDH1A1TSHRL3MBTL1TDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415847-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-3860999-B9 | DERIVATIVES OF RELEBACTAM AND USES THEREOF | ARIXA PHARMACEUTICALS INC (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3860999-B1 | DERIVATIVES OF RELEBACTAM AND USES THEREOF | ARIXA PHARMACEUTICALS INC (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-3625233-B9 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROPANOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3625233-B9 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROPANOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3625233-B1 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROPANOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS INC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3625233-B1 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROPANOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS INC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230201218-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230201218-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230201218-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-10280161-B2 | Aztreonam derivatives and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-10280161-B2 | Aztreonam derivatives and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| WO-2019070595-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019070595-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20190100516-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-04-04 | — | — | US | disclosed |
| US-20190100516-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-04-04 | — | — | US | disclosed |
| US-20190022102-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-01-24 | — | — | US | disclosed |
| US-20190022102-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-01-24 | — | — | US | disclosed |
| WO-2018208557-A1 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROP NOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| US-10085999-B1 | Beta-lactamase inhibitors and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2018-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280161-B2 | Aztreonam derivatives and uses thereof | MGAM, ABCG2, SI | ADRB2 2487/4885ADRB1 1833/4885ADRB3 1711/4885 |
| US-20190022102-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | MGAM, LCT, CMBL | ADRB2 1616/4885ADRB1 1104/4885ADRB3 2026/4885 |
| US-20190100516-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | MGAM, ABCG2, SI | ADRB2 2487/4885ADRB1 1833/4885ADRB3 1711/4885 |
| US-20230201218-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | GAA, LCT, MGAM | ADRB2 1452/4885ADRB1 1056/4885ADRB3 1875/4885 |
| US-10085999-B1 | Beta-lactamase inhibitors and uses thereof | GAA, LCT, MGAM | ADRB2 1452/4885ADRB1 1056/4885ADRB3 1875/4885 |
| US-20240415847-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | GAA, LCT, MGAM | ADRB2 1452/4885ADRB1 1056/4885ADRB3 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.